Antoni Ribas

UNVERIFIED PROFILE

Are you Antoni Ribas?   Register this Author

Register author

Antoni Ribas

Publications by authors named "Antoni Ribas"

Are you Antoni Ribas?   Register this Author

100Publications

-Reads

Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs.

J Control Release 2018 Jul 9;282:156-165. Epub 2018 May 9.

Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 420 Westwood Plaza, 5531 Boelter Hall, Los Angeles, CA 90095, United States; Department of Biomedical Engineering, Duke Univeristy, 101 Science Drive, PO Box 90281, 27708, United States. Electronic address:

View Article
July 2018

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

J Clin Oncol 2018 Jun 28;36(17):1668-1674. Epub 2017 Dec 28.

Caroline Robert, Gustave Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Adil Daud, University of California, San Francisco, San Francisco, CA; Jedd D. Wolchok, Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY; Anthony M. Joshua, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H Lee Moffitt Cancer Center, Tampa; Richard W. Joseph, Mayo Clinic Cancer Center-Florida, Jacksonville, FL; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia, Wollstonecraft; and Macquarie University, MQ Health, Health Sciences Centre; Peter Hersey, University of Sydney, Sydney, New South Wales, Australia; Jin Zhang, James Anderson, Scott J. Diede, and Scot Ebbinghaus, Merck & Co., Inc., Kenilworth, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA.

View Article
June 2018

Immunotherapy resistance by inflammation-induced dedifferentiation.

Cancer Discov 2018 Jun 13. Epub 2018 Jun 13.

Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles

View Article
June 2018

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.

Cancer Cell 2018 May 12;33(5):890-904.e5. Epub 2018 Apr 12.

Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Building 114, Los Angeles, CA 90095, USA; Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA; UCLA Metabolomics Center, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA; California NanoSystems Institute, UCLA, Los Angeles, CA 90095, USA. Electronic address:

View Article
May 2018

Anti-PD-1 antibody treatment for melanoma.

Lancet Oncol 2018 May;19(5):e219

Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article
May 2018

The new era of adjuvant therapies for melanoma.

Nat Rev Clin Oncol 2018 May 30. Epub 2018 May 30.

Department of Medicine, Division of Hematology and Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.

View Article
May 2018

Antigen Presentation Keeps Trending in Immunotherapy Resistance.

Clin Cancer Res 2018 Apr 19. Epub 2018 Apr 19.

Jonsson Comprehensive Cancer Center, Los Angeles, California.

View Article
April 2018

Cancer immunotherapy using checkpoint blockade.

Science 2018 03 22;359(6382):1350-1355. Epub 2018 Mar 22.

Department of Medicine, Ludwig Center and Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article
March 2018

Endocrinopathies with use of cancer immunotherapies.

Clin Endocrinol (Oxf) 2018 Feb 9;88(2):327-332. Epub 2017 Oct 9.

Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.

View Article
February 2018

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Melanoma Res 2017 Dec;27(6):585-590

aDepartment of Internal Medicine, Advocate Medical Group - Oncology North, Park Ridge, Illinois bMelanoma Research Clinic, University of Colorado Cancer Center, Aurora, Colorado cDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia dDepartment of Hematology and Oncology, The University of Arizona Cancer Center, Tucson, Arizona eDepartment of Medicine, Washington University School of Medicine, St Louis, Missouri fDepartment of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee gDepartment of Surgery, Columbia University Medical Center, New York, New York hDepartment of Medical Oncology, Texas Oncology, Dallas, Texas iDepartment of Medicine, Jonsson Comprehensive Cancer Center at University of California jDepartment of Immuno-Oncology, The Angeles Clinic and Research Institute, Los Angeles kDepartment of Oncology, Moores Cancer Center, University of California, San Diego, La Jolla lGenentech Inc., South San Francisco, California mMid Ohio Oncology and Hematology Inc., Columbus, Ohio nDepartment of Melanoma, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC oDepartment of Pathology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania pDepartment of Melanoma, Carol G. Simon Cancer Center, Atlantic Health System, Morristown, New Jersey, USA.

View Article
December 2017

High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

Cancer Med 2017 Nov 10;6(11):2576-2585. Epub 2017 Oct 10.

Wayne State University/Karmanos Cancer Institute, Detroit, Michigan.

View Article
November 2017

Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.

Leuk Lymphoma 2017 Oct 23:1-12. Epub 2017 Oct 23.

b Department of Medicine , University of California at Los Angeles Jonsson Comprehensive Cancer Center , Los Angeles , CA , USA.

View Article
October 2017

New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.

Cancer J 2017 Jan/Feb;23(1):10-22

From the Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA.

View Article
August 2017

Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Nat Rev Clin Oncol 2017 Aug 4;14(8):463-482. Epub 2017 Apr 4.

Melanoma Institute Australia, The University of Sydney, and The Mater Hospital, Rocklands Road, North Sydney, New South Wales 2060, Australia.

View Article
August 2017

Collaborative Care in Melanoma: The Essential Role of the Nurse
.

Clin J Oncol Nurs 2017 08;21(4 Suppl):4-6

University of California, Los Angeles Jonsson Comprehensive Cancer Center.

View Article
August 2017

SnapShot: Immune Checkpoint Inhibitors.

Cancer Cell 2017 06;31(6):848-848.e1

Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.

View Article
June 2017

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

Cell Rep 2017 05;19(6):1189-1201

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA; Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA. Electronic address:

View Article
May 2017

Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping.

Biotechniques 2017 03 1;62(3):123-130. Epub 2017 Mar 1.

Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA.

View Article
March 2017

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.

Invest New Drugs 2017 02 21;35(1):47-58. Epub 2016 Sep 21.

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

View Article
February 2017

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.

Cancer Immunol Res 2017 02 30;5(2):118-126. Epub 2016 Dec 30.

Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

View Article
February 2017

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Cell 2017 Feb;168(4):707-723

Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA. Electronic address:

View Article
February 2017

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J Clin Oncol 2016 Dec 31;34(34):4102-4109. Epub 2016 Oct 31.

Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.

View Article
December 2016

What does PD-L1 positive or negative mean?

J Exp Med 2016 Dec 30;213(13):2835-2840. Epub 2016 Nov 30.

Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095.

View Article
December 2016

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

Eur J Cancer 2016 11 2;67:46-54. Epub 2016 Sep 2.

Department of Medicine, Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center (JCCC) at the University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA 90095, USA. Electronic address:

View Article
November 2016

Cancer Research in the 21st Century.

Ann Surg 2016 10;264(4):555-65

University of California Los Angeles, Los Angeles, California.

View Article
October 2016

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.

Cancer Immunol Res 2016 10 2;4(10):845-857. Epub 2016 Sep 2.

Division of Hematology/Oncology, Department of Medicine, University of California (UCLA), Los Angeles, California. Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California. Jonsson Comprehensive Cancer Center (JCCC) at UCLA, Los Angeles, California. Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, California.

View Article
October 2016

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

N Engl J Med 2016 Sep 13;375(9):819-29. Epub 2016 Jul 13.

From the University of California, Los Angeles (UCLA) (J.M.Z., A.G.-D., D.S.S., H.E.-O., W.H., S.H.-L., D.Y.T., G.A.-R., S.S., L.B., J.S., B.H.M., B.C., K.R., I.P.S., P.J.S., C.P.-S., G.C., E.S., X.K., J.P., B.B.-M., B.C.-A., T.G.G., P.C.T., R.S.L., A.R.), and Jonsson Comprehensive Cancer Center (B.C., B.C.-A., T.G.G., P.C.T., R.S.L., A.R.) - both in Los Angeles; and the Division of Immunology, Netherlands Cancer Institute, Amsterdam (R.M., T.N.M.S.).

View Article
September 2016

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma.

Cell Discov 2016 6;2:16028. Epub 2016 Sep 6.

Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; California NanoSystems Institute, University of California Los Angeles, Los Angeles, CA, USA.

View Article
September 2016

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.

Oncoimmunology 2016 Jul 17;5(7):e1052212. Epub 2015 Aug 17.

Department of Medicine; Division of Hematology/Oncology; University of California, Los Angeles (UCLA); Los Angeles, CA USA; Department of Molecular and Medical Pharmacology; University of California, Los Angeles (UCLA); Los Angeles, CA USA; The Jonsson Comprehensive Cancer Center (JCCC); University of California, Los Angeles (UCLA); Los Angeles, CA USA; Surgery; Division of Surgical Oncology; University of California, Los Angeles (UCLA); Los Angeles, CA USA.

View Article
July 2016

CRAF R391W is a melanoma driver oncogene.

Sci Rep 2016 06 8;6:27454. Epub 2016 Jun 8.

Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.

View Article
June 2016

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J Clin Oncol 2016 05 7;34(13):1510-7. Epub 2016 Mar 7.

F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Richard Kefford, Westmead Hospital, Melanoma Institute Australia, and Macquarie University; Peter Hersey, University of Sydney, Sydney, Australia; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; Adil Daud, University of California San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute; Antoni Ribas, University of California Los Angeles, Los Angeles, CA; Caroline Robert, Gustave-Roussy and Paris-Sud University, Villejuif-Paris-Sud, France; Tara C. Gangadhar, Abramson Cancer Center, Philadelphia, PA; Anthony M. Joshua, Princess Margaret Hospital, Toronto, Ontario, Canada; Roxana Dronca, Mayo Clinic, Rochester, MN; Darcy Hille, Dahai Xue, Xiaoyun Nicole Li, S. Peter Kang, Scot Ebbinghaus, and Andrea Perrone, Merck, Kenilworth, NJ; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article
May 2016

CANCER IMMUNOLOGY. The "cancer immunogram".

Science 2016 May;352(6286):658-60

Division of Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.

View Article
May 2016

Combination cancer immunotherapies tailored to the tumour microenvironment.

Nat Rev Clin Oncol 2016 Mar 24;13(3):143-58. Epub 2015 Nov 24.

Cancer Immunoregulation and Immunotherapy Laboratory QIMR Berghofer Medical Research Institute, Herston, 4006 Queensland, Australia.

View Article
March 2016

Single-cell analysis tools for drug discovery and development.

Nat Rev Drug Discov 2016 Mar 16;15(3):204-16. Epub 2015 Dec 16.

Ludwig Institute for Cancer Research San Diego, Department of Pathology and Moores Cancer Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA.

View Article
March 2016

PD-1 Blockade Expands Intratumoral Memory T Cells.

Cancer Immunol Res 2016 Mar 19;4(3):194-203. Epub 2016 Jan 19.

Division of Surgical-Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California. Jonsson Comprehensive Cancer Center, Los Angeles, California.

View Article
March 2016

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Cell 2016 Mar 17;165(1):35-44. Epub 2016 Mar 17.

Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095-1662, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA. Electronic address:

View Article
March 2016

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

Semin Immunol 2016 02 6;28(1):73-80. Epub 2016 Feb 6.

Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center (JCCC) at UCLA, Los Angeles, CA 90095, USA. Electronic address:

View Article
February 2016

An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.

Cancer Res 2016 Jan 16;76(1):73-82. Epub 2015 Nov 16.

Crump Institute for Molecular Imaging, University of California Los Angeles, Los Angeles, California. Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California. Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.

View Article
January 2016

Targeted Therapy for Melanoma.

Cancer Treat Res 2016 ;167:251-62

Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles (UCLA), Le Conte Avenue, Los Angeles, CA, 10833, USA.

View Article
January 2016

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.

Ther Adv Med Oncol 2016 Jan;8(1):48-56

Department of Medicine, Division of Hematology-Oncology, UCLA, 11-934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA.

View Article
January 2016

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Eur J Cancer 2015 Nov 10;51(17):2689-97. Epub 2015 Sep 10.

Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. Electronic address:

View Article
November 2015

Releasing the Brakes on Cancer Immunotherapy.

Authors:
Antoni Ribas

N Engl J Med 2015 Oct 8;373(16):1490-2. Epub 2015 Sep 8.

From the Department of Medicine, Division of Hematology-Oncology, and the Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles.

View Article
October 2015

Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Authors:
Antoni Ribas

Cancer Discov 2015 Sep 13;5(9):915-9. Epub 2015 Aug 13.

Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, Los Angeles, California.

View Article
September 2015

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

Cell 2015 Sep;162(6):1271-85

Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1662, USA. Electronic address:

View Article
September 2015

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma.

Mol Cancer 2015 Jul 2;14:128. Epub 2015 Jul 2.

Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles (UCLA), 11-934 Factor Building, Los Angeles, CA, USA.

View Article
July 2015

Anti-PD-1 therapy in melanoma.

Semin Oncol 2015 Jun 13;42(3):466-73. Epub 2015 Feb 13.

Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles (UCLA), CA; Department of Surgery, University of California Los Angeles (UCLA), Los Angeles, CA; Department of Medical and Molecular Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA; Jonsson Comprehensive Cancer Center (JCCC) at UCLA, Los Angeles, CA. Electronic address:

View Article
June 2015

Classifying Cancers Based on T-cell Infiltration and PD-L1.

Cancer Res 2015 Jun;75(11):2139-45

School of Medicine, University of Queensland, Herston, Queensland, Australia. Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article
June 2015

Excluding T Cells: Is β-Catenin the Full Story?

Cancer Cell 2015 Jun;27(6):749-50

Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Surgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Medical and Molecular Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center (JCCC) at UCLA, Los Angeles, CA 90095, USA. Electronic address:

View Article
June 2015

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.

BMC Cancer 2015 May 5;15:356. Epub 2015 May 5.

Department of Molecular and Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.

View Article
May 2015